Institution
Flinders Medical Centre
Healthcare•Bedford Park, South Australia, Australia•
About: Flinders Medical Centre is a healthcare organization based out in Bedford Park, South Australia, Australia. It is known for research contribution in the topics: Population & Medicine. The organization has 4696 authors who have published 7369 publications receiving 214110 citations.
Topics: Population, Medicine, Cancer, Randomized controlled trial, Antigen
Papers published on a yearly basis
Papers
More filters
••
TL;DR: This new adenocarcinoma classification is needed to provide uniform terminology and diagnostic criteria, especially for bronchioloalveolar carcinoma (BAC), the overall approach to small nonresection cancer specimens, and for multidisciplinary strategic management of tissue for molecular and immunohistochemical studies.
3,850 citations
••
TL;DR: Patients with a colorectal tumor bearing mutated K-ras did not benefit from cetuximab, whereas patients with a tumor bearing wild-type K-ra did benefit fromcetuxIMab.
Abstract: BACKGROUND Treatment with cetuximab, a monoclonal antibody directed against the epidermal growth factor receptor, improves overall and progression-free survival and preserves the quality of life in patients with colorectal cancer that has not responded to chemotherapy. The mutation status of the K-ras gene in the tumor may affect the response to cetuximab and have treatment-independent prognostic value. METHODS We analyzed tumor samples, obtained from 394 of 572 patients (68.9%) with colo rectal cancer who were randomly assigned to receive cetuximab plus best supportive care or best supportive care alone, to look for activating mutations in exon 2 of the K-ras gene. We assessed whether the mutation status of the K-ras gene was associated with survival in the cetuximab and supportive-care groups. RESULTS Of the tumors evaluated for K-ras mutations, 42.3% had at least one mutation in exon 2 of the gene. The effectiveness of cetuximab was significantly associated with K-ras mutation status (P = 0.01 and P<0.001 for the interaction of K-ras mutation status with overall survival and progression-free survival, respectively). In patients with wild-type K-ras tumors, treatment with cetuximab as compared with supportive care alone significantly improved overall survival (median, 9.5 vs. 4.8 months; hazard ratio for death, 0.55; 95% confidence interval [CI], 0.41 to 0.74; P<0.001) and progression-free survival (median, 3.7 months vs. 1.9 months; hazard ratio for progression or death, 0.40; 95% CI, 0.30 to 0.54; P<0.001). Among patients with mutated K-ras tumors, there was no significant difference between those who were treated with cetuximab and those who received supportive care alone with respect to overall survival (hazard ratio, 0.98; P = 0.89) or progression-free survival (hazard ratio, 0.99; P = 0.96). In the group of patients receiving best supportive care alone, the mutation status of the K-ras gene was not significantly associated with overall survival (hazard ratio for death, 1.01; P = 0.97). CONCLUSIONS Patients with a colorectal tumor bearing mutated K-ras did not benefit from cetuximab, whereas patients with a tumor bearing wild-type K-ras did benefit from cetuximab. The mutation status of the K-ras gene had no influence on survival among patients treated with best supportive care alone. (ClinicalTrials.gov number, NCT00079066.)
3,477 citations
••
TL;DR: The International Study Group of Pancreatic Surgery (ISGPS) developed an objective and generally applicable definition with grades of delayed gastric emptying (DGE) based primarily on severity and clinical impact as discussed by the authors.
2,150 citations
••
TL;DR: An objective, universally accepted definition and clinical grading of PPH is important for the appropriate management and use of interventions in PPH and would allow comparisons of results from future clinical trials.
1,790 citations
•
TL;DR: A study was undertaken to investigate possible changes in microRNA levels during tumorigenesis, identifying a total of 28 different miRNA sequences, including 3 novel sequences and a further 7 that had previously been cloned only from mice.
Abstract: Short non-coding RNAs are known to regulate cellular processes including development, heterochromatin formation, and genomic stability in eukaryotes. Given the impact of these processes on cellular identity, a study was undertaken to investigate possible changes in microRNA (miRNA) levels during tumorigenesis. A total of 28 different miRNA sequences was identified in a colonic adenocarcinoma and normal mucosa, including 3 novel sequences and a further 7 that had previously been cloned only from mice. Human homologues of murine miRNA sequences, miR-143 and miR-145, consistently display reduced steady-state levels of the mature miRNA at the adenomatous and cancer stages of colorectal neoplasia.
1,703 citations
Authors
Showing all 4713 results
Name | H-index | Papers | Citations |
---|---|---|---|
Christopher Hill | 144 | 1562 | 128098 |
Stephen T. Holgate | 142 | 870 | 82345 |
Tony L. Yaksh | 123 | 806 | 60898 |
Peter Somogyi | 112 | 232 | 42450 |
Michael Horowitz | 112 | 982 | 46952 |
Glenda M. Halliday | 111 | 676 | 53684 |
Eamonn Martin Quigley | 103 | 685 | 39585 |
John B. Furness | 103 | 597 | 37668 |
Craig S. Anderson | 101 | 650 | 49331 |
John Chalmers | 99 | 831 | 55005 |
Sebastian L. Johnston | 99 | 512 | 42346 |
Philip J. Barter | 96 | 466 | 56118 |
Ken Shortman | 94 | 299 | 38539 |
Peter J. Allen | 88 | 456 | 42791 |
James McCluskey | 85 | 408 | 25520 |